Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03581877 · ClinicalTrials.gov registry record · Phase 4
Peripheral Systemic Thrombolysis Versus Catheter Directed Thrombolysis for Submassive PE
A Phase 4 study of Pulmonary Hypertension and Pulmonary Embolism, sponsored by Northwell Health.
- Active
- Registry status
- Phase 4
- Development phase
- 31
- Enrollment target
- 2
- Study locations
NCT03581877 is a Phase 4 study of Pulmonary Hypertension and Pulmonary Embolism that is active but no longer recruiting, run by Northwell Health. The registered enrollment target is 31 participants, below the 613-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT03581877, a Phase 4 study of Pulmonary Hypertension and Pulmonary Embolism, is active but no longer recruiting, sponsored by Northwell Health.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 31 participants
- Enrollment target
- 2
- Study locations
Study Summary
To determine whether peripheral low dose systemic thrombolysis (PLST) is non-inferior to catheter directed acoustic pulse thrombolysis (ACDT) in improving RV function and reducing pulmonary artery pressures in submassive pulmonary embolism (PE)
Conditions Studied
Interventions
- DRUG Alteplase
- DEVICE EKOS
Study Locations (2)
New York
- Southside Northwell Hospital - Bay Shore
- Long Island Jewish Medical Center - Queens
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2019-01-28 |
| Est. Completion | 2025-03-19 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03581877
The ClinicalTrials.gov registry entry for NCT03581877 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 613-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (95% lower). The listed sponsor is Northwell Health, which has 370 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Pulmonary Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Alteplase is the first listed.
NCT03581877 reports 2 study locations spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT03581877 about?
NCT03581877 is a clinical study titled "Peripheral Systemic Thrombolysis Versus Catheter Directed Thrombolysis for Submassive PE". To determine whether peripheral low dose systemic thrombolysis (PLST) is non-inferior to catheter directed acoustic pulse thrombolysis (ACDT) in improving RV function and reducing pulmonary artery pressures in submassive pulmonary embolism (PE)
What is the current status of trial NCT03581877?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 31 participants. The study started on 2019-01-28. Estimated completion is 2025-03-19.
What conditions does trial NCT03581877 study?
This clinical trial studies the following conditions: Pulmonary Hypertension, Pulmonary Embolism, Thromboembolism, Right Ventricular Dysfunction.
What interventions are being tested in trial NCT03581877?
The interventions under investigation include: Alteplase (DRUG), EKOS (DEVICE).
Who is sponsoring clinical trial NCT03581877?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03581877 being conducted?
This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Ranolazine in the Treatment of Pulmonary Hypertension Associated With Diastolic Left Ventricular Dysfunction
COMPLETED · Phase 4
-
Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan
COMPLETED · Phase 4
-
A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis
COMPLETED · Phase 4
-
Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection
RECRUITING
-
Development of an Algorithm to Detect Pulmonary Hypertension Using an Electronic Stethoscope
RECRUITING
-
Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.